RxDoctor Payments Data

Shaukat Khan, MD

Cardiovascular Disease · Burlington, NCNPI 1477549871

Payments from drug & device makers

$4,753in general payments, 2019–2025

Across 317 payments — averaging $14.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$767
  • Novartis$504
  • E.r. Squibb & Sons, L.L.C.$383
  • Merck$354
  • AstraZeneca$287
  • Esperion Therapeutics, Inc.$247
  • plus $2K from 29 others

What the payments were for

  • Food & beverage$4,753100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,753 in reported general payments places this provider in the 60th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$76,017
Medicare patients
321
Services billed
1,969

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban250$224,126
EntrestoSacubitril/Valsartan88$100,756
FarxigaDapagliflozin Propanediol102$70,776
XareltoRivaroxaban63$58,330
Repatha SureclickEvolocumab54$43,718
BrilintaTicagrelor44$28,098
JardianceEmpagliflozin25$25,728
MultaqDronedarone Hcl18$17,243
NexlizetBempedoic Acid/Ezetimibe15$5,826
Ranolazine ErRanolazine96$5,772
Metoprolol Succinate455$4,148
Rosuvastatin Calcium286$2,517
Amiodarone Hcl152$2,201
Losartan Potassium261$1,558
Pantoprazole Sodium190$1,481

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$110$224,126250 claims
NovartisEntresto$504$100,75688 claims
AstraZenecaFarxiga, Brilinta$287$98,874146 claims
Johnson & JohnsonXarelto$110$58,33063 claims
Boehringer IngelheimJardiance$180$25,72825 claims
Sanofi-aventis U.S. LLCMultaq$244$17,24318 claims
Esperion Therapeutics, Inc.Nexlizet$247$5,82615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Burlington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →